Ezgi Sönmez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ezgi Sönmez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Fikriye Kalkan
Department of Allergy and Clinical Immunology, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye
4 shared publications - Ozgur Kartal
Division of Immunology and Allergic Diseases, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
4 shared publications - Sait Yeşillik
Department of Immunology and Allergy, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Türkiye
4 shared publications - Yasemin Akgul Balaban
Department of Immunology and Allergic Diseases, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
4 shared publications - Fevzi Demirel
Immunology and allergy, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
3 shared publications - Mustafa Ilker Inan
Division of Immunology and Allergic Diseases, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
3 shared publications
Latest Publications
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 167-174
Evaluation of sleep, fatigue, and quality of life in patients with primary immunodeficiency
Introduction: Primary immunodeficiency (PID) is a heterogeneous group of genetic disorders characterized by recurrent infections and immune dysregulation. Despite advances in therapy, many patients experience impaired quality of life (QoL), fatigue, and sleep disturbances. This study aimed to evaluate sleep quality, fatigue, and health-related QoL in adults with PID and to explore the associations between comorbidities and treatment modalities.Materials and Methods: This retrospective, observational, single-center study was conducted at the University of Health Sciences, Gülhane Training and Research Hospital between May and August 2024. Forty-nine adult patients with PID, diagnosed according to international criteria, completed validated questionnaires: the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and SF-36 QoL scale. Clinical and demographic data were retrieved from the medical records. Statistical analyses included t-tests, Mann–Whitney U, chi-square, and Pearson’s correlation, with significance set at P < 0.05.Results: Of 49 patients (55.1% males, mean follow-up 9.9 years), 36.7% had poor sleep quality, 42.9% reported severe fatigue, 49% showed impaired SF-36 physical scores, and 87.8% had preserved mental scores. Poor sleep quality was correlated positively with fatigue (r = 0.623, P < 0.001) and negatively correlated with physical QoL (r = −0.491, P < 0.001). Patients with autoimmune and inflammatory bowel disease had significantly worse PSQI and FSS scores, whereas bronchiectasis was associated with reduced SF-36 physical scores. No differences were observed between the IVIG and SCIG groups in fatigue or mental scores; however, SCIG recipients had significantly higher physical scores (P = 0.018).Conclusion: Patients with PID experience substantial impairment in physical QoL, with fatigue and poor sleep quality frequently coexisting. Comorbidities, such as autoimmunity, bronchiectasis, and inflammatory bowel disease, exacerbate these impairments. SCIG therapy confers better physical outcomes than IVIG therapy. Comprehensive care strategies that address psychosocial and physical health are essential for the management of PID.
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 167-174
Evaluation of sleep, fatigue, and quality of life in patients with primary immunodeficiency
Introduction: Primary immunodeficiency (PID) is a heterogeneous group of genetic disorders characterized by recurrent infections and immune dysregulation. Despite advances in therapy, many patients experience impaired quality of life (QoL), fatigue, and sleep disturbances. This study aimed to evaluate sleep quality, fatigue, and health-related QoL in adults with PID and to explore the associations between comorbidities and treatment modalities.Materials and Methods: This retrospective, observational, single-center study was conducted at the University of Health Sciences, Gülhane Training and Research Hospital between May and August 2024. Forty-nine adult patients with PID, diagnosed according to international criteria, completed validated questionnaires: the Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and SF-36 QoL scale. Clinical and demographic data were retrieved from the medical records. Statistical analyses included t-tests, Mann–Whitney U, chi-square, and Pearson’s correlation, with significance set at P < 0.05.Results: Of 49 patients (55.1% males, mean follow-up 9.9 years), 36.7% had poor sleep quality, 42.9% reported severe fatigue, 49% showed impaired SF-36 physical scores, and 87.8% had preserved mental scores. Poor sleep quality was correlated positively with fatigue (r = 0.623, P < 0.001) and negatively correlated with physical QoL (r = −0.491, P < 0.001). Patients with autoimmune and inflammatory bowel disease had significantly worse PSQI and FSS scores, whereas bronchiectasis was associated with reduced SF-36 physical scores. No differences were observed between the IVIG and SCIG groups in fatigue or mental scores; however, SCIG recipients had significantly higher physical scores (P = 0.018).Conclusion: Patients with PID experience substantial impairment in physical QoL, with fatigue and poor sleep quality frequently coexisting. Comorbidities, such as autoimmunity, bronchiectasis, and inflammatory bowel disease, exacerbate these impairments. SCIG therapy confers better physical outcomes than IVIG therapy. Comprehensive care strategies that address psychosocial and physical health are essential for the management of PID.
- Open Access
- 18 January 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (1) , 31-37
Comparação da eficácia em longo prazo e da relação custo‐eficácia de omalizumabe nas doses de 150 mg e 300 mg em pacientes com urticária crônica espontânea
- 18 January 2025
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 100 (1) , 31-37
Open AccessComparação da eficácia em longo prazo e da relação custo‐eficácia de omalizumabe nas doses de 150 mg e 300 mg em pacientes com urticária crônica espontânea
- Open Access
- 5 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (1) , 31-37
Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
- 5 November 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (1) , 31-37
Open AccessComparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria